Many individuals in the Western world suffer from heartburn, acid regurgitation, abdominal pain, or bowel habit disturbances. The reported prevalence of dyspepsia is approximately 25% with similar values for gastro-oesophageal reflux disease. While prevalence rates are stable over time, substantial changes occur in the main symptom profiles of sufferers. The economic costs of dyspepsia are considerable.
- colonic disease
- gastro-oesophageal reflux disease
- symptom profile
- BMI, body mass index
- DDD, defined daily doses
- GORD, gastro-oesophageal reflux disease
- IBS, irritable bowel syndrome
- OR, odds ratio
Statistics from Altmetric.com
Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The author of this paper has received sponsorship for travel and an honorarium from AstraZeneca.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.